---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-046468"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T05:45:23.604834+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oragenics completes acquisition of Odyssey's concussion, NPC drug assets for $1M cash + 8M preferred shares

## Summary
- Paid $1M cash and issued 8M Series F Preferred shares to Odyssey for assets including mTBI (concussion) and NPC drug candidates and nasal delivery device.
- Joseph Michael Redmond appointed President with $396,000 base salary, eligible for 50% performance bonus, and 75,000 stock options at $5.40.
- Kimberly Murphy remains CEO and board member; Redmond reports to her.
- Series F Preferred is convertible into common stock; further details in prior 8-K from October 5, 2023.
- Employment agreement has 1-year initial term with automatic renewal; severance includes 6-12 months base salary under certain conditions.

## SEC filing metadata
- accession: 0001493152-23-046468
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/0001493152-23-046468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-046468
- JSON: https://secwatch.observer/filing/0001493152-23-046468.json
- Plain text: https://secwatch.observer/filing/0001493152-23-046468.txt

## Key facts
- Executive change
  Joseph Michael Redmond was appointed as President at ORAGENICS INC.
  - Action: appointed
  - Role: President
  source text: the Company entered into an Executive Employment Agreement with Joseph Michael Redmond, pursuant to which he will serve as the President of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/0001493152-23-046468-index.htm
- M&A Transactions
  ORAGENICS INC completed an acquisition involving Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. for $1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock (closed 2023-12-28).
  - Action: acquisition
  - Counterparty: Odyssey Health, Inc., f/k/a Odyssey Group International, Inc.
  - Consideration: $1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock
  - Closing: 2023-12-28
  source text: Pick Disease Type C (NPC), as well as Odyssey’s proprietary powder formulation and its nasal delivery device. In consideration for the Purchased Assets, the Company paid Odyssey $1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock to Odyssey. The Series F Preferred Stock is convertible into shares of the Company’s common stock, as
  evidence_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315223046468/0001493152-23-046468-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.